Alzheimer’s drug, the monoclonal antibody lecanemab, slowed decline in a phase 3 clinical trial, the company said.
Related Articles
-
Record number of coronavirus cases reported in several European countries
LONDON — Germany followed several European countries by reporting a record number of daily coronavirus cases on Saturday, as...
-
QAnon supporters join thousands at protest against German coronavirus rules
BERLIN — Thousands of protesters, some waving flags with the symbol of the QAnon conspiracy movement, gathered in the...
-
Is the best strategy against omicron to keep boosting with the original vaccine?
Federal health officials are urging all vaccinated adults to get their Covid booster shot amid growing alarm over the...
-
Teddi Mellencamp, former ‘Real Housewives’ star, reveals she has multiple brain tumors
Teddi Mellencamp, former star of the “‘Real Housewives of Beverly Hills,” revealed that doctors have found multiple tumors on...
-
Covid-19 may make people’s tinnitus worse
Rebecca Edgar, 29, struggles to hear her toddler when he talks to her from the backseat of her car....
-
What we know about Luigi Mangione, person-of-interest in United Healthcare CEO’s shooting death
Pennsylvania authorities on Monday arrested “a strong person of interest” in the shooting death of United Healthcare CEO Brian...
-
Pfizer asks FDA to authorize Covid antiviral pills
Pfizer asked the Food and Drug Administration on Tuesday to authorize its experimental Covid-19 antiviral treatment, Paxlovid. The treatment...
-
HPV-related cervical cancer increasing in some women, new research finds
After decades of good news in the fight against cervical cancer — marked by decades of steady declines in...
Recent Comments